MARKET

IMV

IMV

IMV Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.450
-0.020
-0.58%
After Hours: 3.450 0 0.00% 16:41 11/25 EST
OPEN
3.480
PREV CLOSE
3.470
HIGH
3.510
LOW
3.390
VOLUME
186.36K
TURNOVER
--
52 WEEK HIGH
6.82
52 WEEK LOW
1.350
MARKET CAP
231.47M
P/E (TTM)
-7.7164
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
IMV Q3 EPS $(0.13) Up From $(0.16) YoY
IMV (NASDAQ:IMV) reported quarterly losses of $(0.13) per share. This is a 18.75 percent increase over losses of $(0.16) per share from the same period last year.
Benzinga · 11/12 12:27
IMV reports Q3 results
IMV (IMV): Q3 GAAP EPS of -C$0.13.Revenue of C$0.09M (-43.8% Y/Y)Shares -0.74% PM.Press Release
Seekingalpha · 11/12 12:09
IMV Strengthens Leadership Team with Appointment of Andrew Hall as Chief Business Officer
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced the appointment of Andrew Hall to the newly created role of Chief Business Officer. Mr. Hall will oversee all business development and commercial initiatives for IMV’s pipeline.
Business Wire · 11/10 12:05
IMV's T Cell Therapy Demonstrates 86% Objective Response Rate in Combination with Merck's Keytruda in PD-L1 Positive Patients with r/r DLBCL
Results support the interactive mechanism of action of the combination treatment, and the advancement into a potentially pivotal registration trial 86% (6/7) Objective Response Rate (ORR) in patients positive for
Benzinga · 11/09 13:09
IMV Inc. to Report Third Quarter 2020 Results and Present Biomarkers Associated With Clinical Response in Patients With r/r DLBCL treated with DPX-Survivac Combination Therapy
IMV Inc. to Report Third Quarter 2020 Results and Present Biomarkers
Business Wire · 10/29 12:05
IMV Enters Oversold Territory
IMV has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Zacks · 10/16 08:53
IBM, BHC among premarket gainers
Consumer Portfolio Services (CPSS) +59% on acquisition proposal by Auto Experience.Eaton Vance (EV) +45% as MS agrees to acquire the company for about $7B.DPW Holdings (DPW) +30% on introducing new energy storage system product line.Alphatec Holdings
Seekingalpha · 10/08 12:30
IMV Provides Updates On COVID-19 Vaccine Program; Co. Selected For Additional Canadian Government Funding, Phase 1/2 Study Updated, Collaboration Initiated With A Global Manufacturing Partner
Selected for additional funding by Canadian Government bringing total support to $10M for clinical development and manufacturing of DPX-COVID-19 Clinical plan updated to run a larger Phase 1/2 study with the
Benzinga · 10/08 11:13
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMV. Analyze the recent business situations of IMV Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMV stock price target is 9.32 with a high estimate of 13.08 and a low estimate of 5.03.
EPS
Institutional Holdings
Institutions: 44
Institutional Holdings: 14.19M
% Owned: 21.15%
Shares Outstanding: 67.09M
TypeInstitutionsShares
Increased
9
856.50K
New
19
4.58M
Decreased
6
922.64K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About IMV
IMV Inc. is a clinical stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases, including coronavirus disease 2019 (COVID-19). The Company develops cancer-targeted immunotherapies and vaccines based on the Company’s platform, DPX. The Company’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the platform with a cancer target: survivin. Its T cell therapy is evaluated in phase II clinical trials in ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications. Its T cell therapy, DPX-Survivac, consists of survivin-based peptides formulated in its platform (DPX). DPX-Survivac is designed to generate a cytotoxic T cell response against cancer cells offering survivin peptides on their surface.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Imv Inc stock information, including NASDAQ:IMV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMV stock methods without spending real money on the virtual paper trading platform.